Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer

Oncotarget

Volumn 6, Issue 25, 2015, Pages 21675-21684

  Pértega Gomes, Nelma ^a   Vizcaino, Jose R ^b   Felisbino, Sergio ^c   Warren, Anne Y ^d   Shaw, Greg ^a   Kay, Jonathan ^a,e   Whitaker, Hayley ^a,e   Lynch, Andy G ^a   Fryer, Lee ^a   Neal, David E ^a,f   Massie, Charles E ^a  

^a CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^b Centro Hospitalar Universitario do Porto   (Portugal)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^d CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Castrate resistant disease; Malignant phenotype; Monocarboxylate transporter 2; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; DEGARELIX; MONOCARBOXYLATE TRANSPORTER 2; 5' UNTRANSLATED REGION; AR PROTEIN, HUMAN; ERG PROTEIN, HUMAN; MONOCARBOXYLATE TRANSPORTER; SLC16A7 PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR ERG;

5' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; DEMETHYLATION; EPIGENETICS; ETS RELATED GENE; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION; GENE LOCUS; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ONCOGENE; PHENOTYPE; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; SLC16A7 GENE; TRANSCRIPTOMICS; TRANSLATION REGULATION; CONFOCAL MICROSCOPY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; METASTASIS; PROSTATE TUMOR; PROTEIN SYNTHESIS;

5' UNTRANSLATED REGIONS; AMINO ACID MOTIFS; COHORT STUDIES; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, CONFOCAL; MONOCARBOXYLIC ACID TRANSPORTERS; NEOPLASM METASTASIS; PHENOTYPE; PROSTATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTIONAL REGULATOR ERG;

EID: 84940758201     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4328     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
2. Pertega-Gomes N, Vizcaino JR, Gouveia C, Jeronimo C, Henrique RM, Lopes C, Baltazar F. Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. Prostate. 2013; 73:763-769.
3. Pertega-Gomes N, Vizcaino JR, Miranda-Goncalves V, Pinheiro C, Silva J, Pereira H, Monteiro P, Henrique RM, Reis RM, Lopes C, Baltazar F. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer. 2011; 11:312.
4. Lin RY, Vera JC, Chaganti RS, Golde DW. Human monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter. J Biol Chem. 1998; 273:28959-28965.
5. Broer S, Broer A, Schneider HP, Stegen C, Halestrap AP, Deitmer JW. Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J. 1999; 341:529-535.
6. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 2006; 66:632-637.
7. Mathupala SP, Parajuli P, Sloan AE. Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study. Neurosurgery. 2004; 55:1410-1419.
8. Lee I, Lee SJ, Kang WK, Park C. Inhibition of monocarboxylate transporter 2 induces senescence-associated mitochondrial dysfunction and suppresses progression of colorectal malignancies in vivo. Mol Cancer Ther. 2012; 11:2342-2351.
9. Cai C, Wang H, Xu Y, Chen S, Balk SP. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res. 2009; 69:6027-6032.
10. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010; 17:443-454.
11. Massie CE, Mills IG. Global identification of androgen response elements. Methods Mol Biol. 2011; 776:255-273.
12. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, Bonke M, Jolma A, Varjosalo M, Gehrke AR, Yan J, Talukder S, Turunen M, et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J. 2010; 29:2147-2160.
13. Lin B, Wang J, Hong X, Yan X, Hwang D, Cho JH, Yi D, Utleg AG, Fang X, Schones DE, Zhao K, Omenn GS, Hood L. Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS One. 2009; 4:e6589.
14. Mounir Z, Lin F, Lin VG, Korn JM, Yu Y, Valdez R, Aina OH, Buchwalter G, Jaffe AB, Korpal M Zhu P, Brown M, Cardiff RD, et al. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation. Oncogene. 2014.
15. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007; 9:166-180.
16. Dennis G, Jr., Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003, 4:P3.
17. Valenca I, Pertega-Gomes N, Vizcaino JR, Henrique RM, Lopes C, Baltazar F, Ribeiro D. Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer. J Cell Mol Med. 2015.
18. Wei J, Xu G, Wu M, Zhang Y, Li Q, Liu P, Zhu T, Song A, Zhao L, Han Z, Chen G, Wang S, Meng L, et al. Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res. 2008; 28:327-334.
19. Siu MK, Tsai YC, Chang YS, Yin JJ, Suau F, Chen WY, Liu YN. Transforming growth factor-beta promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway. Oncogene. 2014.
20. McClelland GB, Khanna S, Gonzalez GF, Butz CE, Brooks GA. Peroxisomal membrane monocarboxylate transporters: evidence for a redox shuttle system? Biochem Biophys Res Commun. 2003; 304:130-135.
21. Camoes F, Bonekamp NA, Delille HK, Schrader M. Organelle dynamics and dysfunction: A closer link between peroxisomes and mitochondria. J Inherit Metab Dis. 2009, 32:163-180.
22. Le Floch R, Chiche J, Marchiq I, Naiken T, Ilc K, Murray CM, Critchlow SE, Roux D, Simon MP, Pouyssegur J. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumours. Proc Natl Acad Sci U S A. 2011; 108:16663-16668.
23. Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013; 123:3685-3692.
24. Marchiq I, Le Floch R, Roux D, Simon MP, Pouyssegur J. Genetic disruption of lactate/H+ symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin. Cancer Res. 2015; 75:171-180.
25. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5:R80.